KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Raw Materials: 2012-2024

Historic Raw Materials for Supernus Pharmaceuticals (SUPN) over the last 12 years, with Dec 2024 value amounting to $11.1 million.

  • Supernus Pharmaceuticals' Raw Materials rose 392.51% to $57.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.0 million, marking a year-over-year increase of 392.51%. This contributed to the annual value of $11.1 million for FY2024, which is 31.63% down from last year.
  • Supernus Pharmaceuticals' Raw Materials amounted to $11.1 million in FY2024, which was down 31.63% from $16.3 million recorded in FY2023.
  • In the past 5 years, Supernus Pharmaceuticals' Raw Materials ranged from a high of $24.8 million in FY2022 and a low of $7.3 million during FY2021.
  • For the 3-year period, Supernus Pharmaceuticals' Raw Materials averaged around $17.4 million, with its median value being $16.3 million (2023).
  • Its Raw Materials has fluctuated over the past 5 years, first crashed by 67.02% in 2021, then spiked by 238.84% in 2022.
  • Supernus Pharmaceuticals' Raw Materials (Yearly) stood at $22.2 million in 2020, then plummeted by 67.02% to $7.3 million in 2021, then surged by 238.84% to $24.8 million in 2022, then tumbled by 34.43% to $16.3 million in 2023, then crashed by 31.63% to $11.1 million in 2024.